Replies to post #64121 on Amarantus Bioscience Holdings Inc (AMBS)

[lewsogge]

Exactly! They are so damn close to huge milestones... I guess some people just have different definitions of close.

In our meeting with Gerald he could not disclose which diagnostic platform they plan to progress first, but my guess is LymPro. 97% success rate in Phase 1 and $500,000,000 a year expected revenue. That will feed MANF nicely.